Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN® REVEAL Trial

Open access
Shaikh, Nisar A., Yantha, Jason, Shaikh, Sabah, Rowe, William, Laidlaw, Maggie, Cockerline, Carla, Ali, Abbas, Holub, Bruce, Jackowski, George · 2014 · Molecular and Cellular Biochemistry

Abstract

Low blood levels of long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) have been reported to be associated with increased risk for cardiovascular disease (CVD) deaths. Systematic studies measuring LC n-3 PUFA blood levels (pre and post-treatment) in defined subjects, and monitoring the correction of nutritional deficiency with a pure LC n-3 PUFA formulation in sufficient doses, while monitoring CVD risk factors are lacking. We tested the efficacy of a novel LC n-3 PUFA Medical Food formulation (VASCAZEN(®), > 90 % pure with a 6:1 eicosapentaenoic acid-(EPA):docosahexaenoic acid-(DHA) ratio; 6:1-OM3), to correct such deficiency and determine the concomitant effects on lipid profiles. Of 655 subjects screened, 89 % were LC n-3 PUFA deficient (Omega-Score, (OS) = blood EPA + DHA + Docosapentaenoic acid < 6.1 %). From these, a study was conducted on 110 ambulatory cardiovascular subjects. Placebo: corn oil. Primary endpoint: change in OS. Secondary endpoint: changes in blood lipid profiles. At 8 weeks of treatment with 6:1-OM3 (4 g/day), placebo-adjusted median OS levels (n = 56) significantly improved (132 %, P < 0.0001) with a decrease in AA (arachidonic acid): EPA ratio (82 %, P < 0.0001). In hypertriglyceridemic subjects (TG 2.26-5.65 mmol/L), HDL-C improved (9 %, P = 0.0069), TG-reduced (48 %, P < 0.0001), and VLDL-C reduced (30 %, P = 0.0023), without significantly affecting LDL-C levels. This study confirms that LC n-3 PUFA deficiency is prevalent in the US population, and its correction with 6:1-OM3 in CVD subjects improves lipid profiles. The purity, EPA:DHA ratio and dose are determinant factors for optimal efficacy of a formulation in reducing CVD risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11010-014-2132-1

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design and patient disposition
Fig. 1 Study design and patient dispositionCC BY · PubMed Central
Fig. 2 Change in blood median OS (primary endpoint) following 8 weeks of treatment with 6:1-OM3. A Total 6:1-OM3 treated (n = 56) in both Cohorts, B Cohort 1 (baseline TG 1.02–2.25 mmol/L, n = 36), and C Cohort 2 (baseline TG 2.26–5.65 mmol/L, n = 20). Percentage increases (box) represent a significant change (P < 0.0001) in placebo-adjusted median OS from baseline to week 8. Risk quartiles were adapted from previously published data [10]. For abbreviations, see text
Fig. 2 Change in blood median OS (primary endpoint) following 8 weeks of treatment with 6:1-OM3. A Total 6:1-OM3 treated (n = 56) in both Cohorts, B Cohort 1 (baseline TG 1.02–2.25 mmol/L, n = 36), and C Cohort 2 (baseline TG 2.26–5.65 mmol/L, n = 20). Percentage increases (box) represent a significant change (P < 0.0001) in placebo-adjusted median OS from baseline to week 8. Risk quartiles were adapted from previously published data [10]. For abbreviations, see textCC BY · PubMed Central
Fig. 3 Change in OS (primary endpoint) at baseline and upon 8 weeks of treatment with 6:1-OM3 (n = 56). A Frequency distribution plot of panel B subjects with a broad distribution of OS due to weak versus strong responders. B Scatter plot of OS in 6:1-OM3 treated. Weak- and strong responders are circled with solid and dotted lines, respectively and horizontal lines at baseline and 8 week represent median values
Fig. 3 Change in OS (primary endpoint) at baseline and upon 8 weeks of treatment with 6:1-OM3 (n = 56). A Frequency distribution plot of panel B subjects with a broad distribution of OS due to weak versus strong responders. B Scatter plot of OS in 6:1-OM3 treated. Weak- and strong responders are circled with solid and dotted lines, respectively and horizontal lines at baseline and 8 week represent median valuesCC BY · PubMed Central
Fig. 4 Percent change from baseline to week 8 of placebo-corrected blood lipid levels in Cohort 2 subjects (baseline TG 2.26–5.65 mmol/L). Analysis was on the per protocol population. *9.05 % increase (P = 0.0069); **30.20 % decrease (P = 0.0023); ***47.75 % decrease (P = 0.0005)
Fig. 4 Percent change from baseline to week 8 of placebo-corrected blood lipid levels in Cohort 2 subjects (baseline TG 2.26–5.65 mmol/L). Analysis was on the per protocol population. *9.05 % increase (P = 0.0069); **30.20 % decrease (P = 0.0023); ***47.75 % decrease (P = 0.0005)CC BY · PubMed Central
Fig. 5 Time-course change in OS, OI, AA:EPA and n-6:n-3 ratios, and in individual LC n-3 PUFA components (n = 56) in both Cohorts upon 8 weeks of treatment with 6:1-OM3 and with placebo. A Changes in OS and OI. B Changes in inflammatory indicators, and C Changes in individual blood EPA, DPA, and DHA levels. All changes were significant (P < 0.0001) following 4 and 8 weeks of treatment. For abbreviations, see text
Fig. 5 Time-course change in OS, OI, AA:EPA and n-6:n-3 ratios, and in individual LC n-3 PUFA components (n = 56) in both Cohorts upon 8 weeks of treatment with 6:1-OM3 and with placebo. A Changes in OS and OI. B Changes in inflammatory indicators, and C Changes in individual blood EPA, DPA, and DHA levels. All changes were significant (P < 0.0001) following 4 and 8 weeks of treatment. For abbreviations, see textCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 16

Metadata

Authors
Shaikh, N. A., Yantha, J., Shaikh, S., Rowe, W., Laidlaw, M., Cockerline, C., Ali, A., Holub, B., & Jackowski, G.
Affiliations
  • University of Toronto (CA)
  • Pivotal (Canada) (CA)
  • Nutrasource (CA)
Corresponding author
Shaikh, Nisar A.
Venue
Molecular and Cellular Biochemistry
Published
2014-09-04
Volume
396
Issue
1-2
Pages
9-22
ISSN
  • 0300-8177 (ISSN-L)
  • 1573-4919
OpenAlex
W2025159021
Cited by
16
References
55
Citations by year
2025: 1 · 2023: 1 · 2022: 1 · 2020: 3 · 2019: 4 · 2017: 1 · 2016: 2 · 2015: 3
FWCI
1.86
Type
journal article
Language
en
Open access
Locations
  • Molecular and Cellular Biochemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
n-3 long-chain polyunsaturated fatty acids, medical foods, nutritional deficiency, cardiovascular risk factors, lipid profile, hypertriglyceridemia, HDL cholesterol, EPA/DHA ratio, docosapentaenoic acid
MeSH terms
Adult, Aged, Cardiovascular Diseases, Deficiency Diseases, Docosahexaenoic Acids, Fatty Acids, Unsaturated, Female, Humans, Male, Middle Aged, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Arachidonic Acid, Treatment Outcome, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN® REVEAL Trial. https://app.cochat.ai/papers/10.1007/s11010-014-2132-1
The paper
Shaikh, N. A., Yantha, J., Shaikh, S., Rowe, W., Laidlaw, M., Cockerline, C., Ali, A., Holub, B., & Jackowski, G. (2014). Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN® REVEAL Trial. Molecular and Cellular Biochemistry. https://doi.org/10.1007/s11010-014-2132-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.